iLite® ADCC Activity Assay 
Product Line

The iLite ADCC product line, is a reporter gene system which is unique in its set-up.

The product line is engineered to work optimally together and give unparalleled sensitivity for each specific target. 

The iLite ADCC product line include a positive target cell as well as a negative control cell line for each specific target. The control cell line allows screening for unspecific activation of ADCC, giving added value to each experiment.

As the majority of the iLite cell lines, the iLite ADCC Assay Ready Cells also have a secondary luciferase readout, from a luciferase expressed under the control of a constitutive promotor. This enables normalization of each individual readout according to cell number and thereby accounts for any potential matrix effects.

Click the picture to see a bigger picture

Figure 1. The interaction between the reporter gene effector cell and the target cell, generated by the crosslinking of the two cells via a specific drug antibody. The resulting luminescence originates exclusively from this crosslinking and the signaling from the CD16 receptor to the Firefly Luciferase promoter. The strength of the luminescence correlates to the drugs ability to induce ADCC.

All components of the ADCC product line are available individually.

ADCC product line in the Drug Development Process

The activity of many antibody-based therapeutics is mediated in part by their ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and thereby enhancing the bodys own immune response towards dysfunctional cells. By analyzing the ADCC activity induced by different drugs or drug candidates, a measure of both drug potency and unwanted side effects can be provided.

As such, the iLite ADCC product line is a valuable tool for the whole drug development process, measuring the ability of a drug to induce ADCC activity in a straight forward, sensitive and reproducible manner. 

Click the picture to see a bigger picture

Figure 2. When the target cell has been depleted for the specific surface target molecule, the crosslinking between the effector and the target cell cannot be established and hence no luminescence from Firefly Luciferase is generated. However, luminescence from the normalization gene, which is expressed under a constitutive promotor, is still present. 

    Key benefits of iLite® ADCC:

          - Unparalleled sensitivity
          - High serum tolerance
          - Normalization read-out included
          - Internal control available for screening of unspecific activity and reduction of background
          - Easy to use – no culturing required of cells


AVAILABLE - iLite® ADCC Product Line


Regulatory Status


BM5001 iLite® ADCC Effector (V) RUO
BM5011 iLite® ADCC Target HER2 (+) RUO
BM5016 iLite® ADCC Target HER2 (-) RUO
BM5013 iLite® ADCC Target mTNF-alpha (+) RUO
BM5014 iLite® ADCC Target mTNF-alpha (-) RUO
BM5035 iLite® ADCC Target EGFR (+) RUO
BM5036 iLite® ADCC Target EGFR (-) RUO


Interested in trying iLite® ADCC Targets?

Click here to contact us today!


Svar Life Science will continuously expand the iLite® ADCC product line with novel and higly specific target cells.


Follow us on LinkedIn to stay up to date with
news and upcoming launches - including
ADCC CD20 target cells

In accepting delivery of iLite® Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party recipient, and only to use them directly in assays. Svar Life Science iLite® cell-based products are covered by patents which are the property of Svar Life Science AB and any attempt to reproduce the delivered iLite® Assay Ready Cells is an infringement of these patents.

Subscribe to our mailing list

* indicates required